Track topics on Twitter Track topics that are important to you
ImpediMed (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that the first patient has been enrolled in its 200-patient Heart Failure (HF) trial now being conducted at Scripps Memorial Hospital, San Diego, CA. As quoted in the press release: With the first patient … Continued
The post ImpediMed Announces First Patient Enrolled at Scripps Memorial Hospital appeared first on Investing News Network.
Original Article: ImpediMed Announces First Patient Enrolled at Scripps Memorial HospitalNEXT ARTICLE